In its role as an industry research partner, InnoSer is pleased to announce the successful completion of the CARDIOIDS project, a consortium-led initiative led by Professor Leon de Windt at Maastricht University. This project represents a major milestone in...
InnoSer, a leading preclinical contract research organization (CRO), and TissUse, a pioneer in the field of microphysiological systems (MPS) development, are pleased to announce the signing of a strategic co-marketing agreement aimed at promoting the widespread...
In a significant achievement, InnoSer has successfully validated tumorigenicity assay as part of the HEAL project, a major initiative aimed at accelerating the development of an allogeneic iPSC-based heart therapy. This milestone lays out the groundwork for safe and...
Researchers will benefit from InnoSer’s preclinical drug development expertise combined with Hasselt University’s foundational knowledge in Multiple Sclerosis (MS) to advance preclinical MS research. Diepenbeek, Belgium, October 16th, 2024 — InnoSer, a leading...
InnoSer partners with CR2O to offer an integrated drug discovery to clinical trials pipeline. Researchers benefit from a comprehensive service offering, spanning early-stage discovery to phase I-IV trials, with meticulous planning and access to specialized services,...
This strategic acquisition substantially expands InnoSer’s preclinical neurology portfolio, adding in vivo rodent models for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, as well as key rare genetic disease...
